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Background: Anemia often complicates chronic kidney disease (CKD), leading to insufficient 
tissue oxygenation and hypoxic injury, the factor thought to underlie progression from CKD 
to renal failure. Perfluorocarbons are potent oxygen transporters used in organ preservation 
and synthetic blood development. Data are scarce on their relationship with kidney function, 
especially in diabetes where anemia and hypoxia are more prevalent. We investigated the 
relationship of perfluoroalkyl acids (PFAS) with kidney function and variation by diabetes 
and anemia status.
Methods: Data on 53,650 adults (5,210 with diabetes) were obtained from the C8 Health 
Project. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 
m2. Four PFAS were investigated: perfluorohexane sulfonate (PFHxS), perfluorooctanoic acid, 
perfluorooctane sulfonate, and perfluorononanoic acid.
Findings: Each PFAS was positively associated with eGFR among those with CKD or anemia; 
this was the strongest among those with both CKD and anemia, followed by those with CKD 
uncomplicated by anemia. These relationships were more pronounced among those with diabetes 
(all P<0.01). In the absence of both CKD and anemia, PFAS was inversely associated with eGFR. 
Among persons with both anemia and diabetes, when further stratified by CKD stage, compared 
to an eGFR <30, ORs (95% CI) for being in the eGFR ≥ 90, 60–89, 45–59, and 30–45 range, 
respectively, were 3.20 (2.00–5.13), 2.64 (1.83–3.80), 3.18 (2.17–4.67), and 1.99 (1.38–2.86) 
for each ng/dL increase in PFHxS. Results were similar for each PFAS.
Interpretation: PFAS are inversely associated with kidney function in CKD and diabetes, 
with a stronger relation observed when anemia is present.
Keywords: diabetes, anemia, chronic kidney disease, hypoxia, perfluoroalkyl substances
Introduction
Anemia in persons with chronic kidney disease (CKD) is common.1,2 Although impaired 
kidney function is thought to be the primary cause of anemia in CKD,3 particularly 
among those without diabetes, low hemoglobin which is characteristic of anemia 
results in reduced renal tissue oxygen delivery and thus renal ischemia.1 Renal hypoxia, 
when chronic, may lead to interstitial fibrosis and sclerosis. Hypoxic injury in CKD 
is thought to be the common underlying mechanism of progression to renal failure 
regardless of the etiology of the kidney disease.4,5
Perfluoroalkyl acids (PFAS), a class of perfluorocarbons, are synthetic environmen-
tal contaminants with detectable levels observed in over 90% of the US population. 
Possessing both hydrophobic and oleophobic characteristics, they are industrial com-
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pounds used in the manufacture of a wide range of industrial 
and consumer products, with waterproofing, nonstick, lubri-
cating, or fire suppression utility, such as in Teflon cooking 
products and waterproof surfactants.6 Because their strong 
carbon-fluorine bonds resist environmental degradation, 
PFAS are persistent environmental contaminants found in the 
serum of the majority of the human populations studied.6,7 
These environmental pollutants have been linked to adverse 
health outcomes,6,8–10 including birth defects and certain 
cancers.11–13 Their long biological half-lives of approximately 
3.0–8 years and their poor ability to metabolize likely add to 
any chronic health effects they may pose.8,14–18
Perfluorocarbons are oxygen carriers and, as such, they 
have been tested for use in developing synthetic blood.19–21 
Perfluorocarbons have also been used in the preservation 
of harvested pancreases and kidneys for transplants.22 
The high oxygen transport capacity of perfluorocarbons 
has been shown to reduce the hypoxia-induced damage 
associated with organ preservation, such as for the kid-
ney and pancreas.22–26 In experimental models, retrograde 
renal perfusion with perfluorocarbon emulsion has also 
been shown to increase systemic venous oxygenation and 
renal preservation.27 There was higher systemic venous 
oxygenation, a lower decrease in creatinine clearance, and 
less histological evidence of ischemic damage.27 However, 
earlier data in experimental studies suggested that per-
fluorocarbon emulsion was associated with greater renal 
function impairment.28
Although PFAS have also been recently shown to have 
cytotoxic potential and to induce inflammation, processes 
that could adversely affect kidney function,29 the association 
of PFAS with chronic disease may vary in diseases char-
acterized by chronic hypoxia, such as diabetes and kidney 
disease.4,30 This is particularly important given the relatively 
high prevalence of anemia among persons with both diabetes 
and CKD. For a given level of kidney function, there is a 
greater prevalence of anemia among persons with diabe-
tes relative to those without diabetes. Furthermore, while 
anemia is rarely observed before stage 3 CKD is reached 
among persons without diabetes, anemia is still common at 
higher levels of kidney function in the diabetic population. 
Data in humans on the effect of PFAS on kidney function 
and CKD are scarce, especially in diabetes where kidney 
hypoxia is more prevalent.31,32 Renal hypoxia occurs prior 
to other manifestations of kidney disease.33 Attenuating this 
hypoxia may slow the development of kidney disease. Given 
the hypothesized role of chronic hypoxia on progression of 
CKD,4 we investigated the relationship of PFAS with kidney 
function and whether any such association varied by diabetes, 
anemia, or CKD status.
Methods
The C8 Health Project is a community-based study that inves-
tigates the health effects of exposure to perfluorooctanoic acid 
(PFOA/C8).34 The C8 Health Project was created as part of a 
settlement after it was found that PFOA had contaminated the 
drinking water of six water districts in the mid-Ohio Valley 
in West Virginia and Ohio between 1950 and 2004. A post 
hoc agreement between the settling parties of the class action 
lawsuit created the C8 Health Project, a community-based 
health survey designed to investigate the effects of exposure 
to PFOA-contaminated drinking water.34 From August 2005 
to August 2006, baseline data were gathered on 69,030 indi-
viduals working or living in six PFOA-contaminated water 
districts in West Virginia and Ohio, including those exposed 
to contaminated private-well drinking water. The estimated 
participation rate in the C8 Health Project among adult resi-
dents of the affected water districts was 81%.35 Data from 
the C8 Health Project (n=69,030) were obtained for use in 
the current study.
The enrollment and data collection methods for the C8 
Health Project have been described in detail previously.34 The 
health survey collected a wide range of serum and anthro-
pometric measures, as well as self-reported clinician diag-
noses of medical conditions. Brookmar Inc. (Parkersburg, 
WV, USA) administered the consent process and conducted 
the data collection. We obtained institutional review board 
approval at West Virginia University for access to the C8 
Health Project de-identified data for this study.
Diabetes was based on self-report of a physician diagno-
sis of diabetes. There were 14,573 children and adolescents 
under the age of 20 years and they were excluded from the 
analysis. Of the remaining 54,102 study participants, 5,296 
reported a physician diagnosis of diabetes. Of the 5,296 with 
diabetes and 49,161 without diabetes, 26 and 329, respec-
tively, had missing data on the four major perfluorocarbons 
of interest, and another 60 persons with diabetes and 392 
without diabetes had missing data on variables needed to 
calculate estimated glomerular filtration rate (eGFR), ie, 
race, sex, or serum creatinine. Our final study population 
thus comprised 53,650 adults, including 5,210 individuals 
with and 48,440 without diabetes.
Perfluorocarbons (PFAS) were assayed using the protein 
precipitation extraction method with reverse phase high-per-
formance liquid chromatography/tandem mass spectrometry. 
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PFAS and renal function in CKD and diabetes
tion monitoring mode, monitoring for the M/Z transitions of 
PFAS species with an internal 13C PFAS standard correspond-
ing to the target compound, was utilized for detection of each 
PFAS. Twelve PFAS were tested; however, only four were 
detectable in the serum of over 90% of project participants: 
perfluorohexane sulfonate (PFHxS), PFOA, perfluorooctane 
sulfonate (PFOS), and perfluorononanoic acid (PFNA). Thus, 
these four compounds were the focus of the current study.
Anemia was defined as a hemoglobin of <13.0 g/dL in 
men and <12 g/dL in women. Hemoglobin was measured in 
EDTA anticoagulated whole blood. Creatinine was measured 
using a kinetic rate Jaffe method.36 eGFR was calculated 
based on the CKD-EPI formula.37 CKD was defined as an 
eGFR of <60 mL/min/1.73 m2.
General linear models were used to test for differences in 
continuous variables, and the chi square test was used to test 
for differences in categorical data. Logistic regression was 
used to estimate the relationship of each of the PFAS with 
CKD. Linear regression analysis using general linear models 
was also used to estimate the relationship between each of 
the PFAS with eGFR, stratified by anemia and CKD status. 
Separate models were constructed to test for a linear trend in 
the beta coefficients in the PFAS–eGFR relationship in the 
four anemia-CKD groups (CKD and anemia, CKD without 
anemia, anemia without CKD, neither CKD nor anemia) 
for each PFAS. Multinomial logistic regression was used to 
assess the relationship of PFAS with multiple stages of kidney 
function impairment, with eGFR (mL/min/1.73 m2) stratified 
into the following categories: ≥90 (normal), 60–89 (mild 
kidney impairment), 45–59 (stage 3a CKD), 30–44 (stage 
3b CKD), and <30 (stages 4–5 CKD). Multivariable models 
included age, sex, and diabetes duration (in diabetes-specific 
analyses), body mass index (BMI), lipids, white blood cell 
count, C-reactive protein (CRP), hemoglobin, and iron. We 
tested for effect modification by diabetes and CKD status on 
the effect of PFOA and PFOS with eGFR. The criterion for 
statistical significance was a two-tailed P-value of <0.10 for 
effect modification and <0.05 otherwise. Statistical analysis 
was conducted using SAS version 9.4 (Cary, NC, USA).
Results
Characteristics of the study participants by diabetes status 
are presented in Table 1. Persons with diabetes tended to be 
older and have a higher BMI and a lower eGFR, and were 
three times more likely to have CKD. They were also three 
times more likely to have anemia, an increased prevalence 






age, years 57.8±13.5 45.1±15.4 <0.0001
Sex, male 49.5 (2,577) 47.2 (22,862) 0.002
Race, White 96.3 (5,017) 97.4 (47,166) <0.0001
Diabetes duration, years 5.6 (2.3–11.8) – –
BMI, m/kg2 33.1±7.5 28.3±6.1 <0.0001
egFr, ml/min/1.73 m2 77.4±22.5 88.1±19.1 <0.0001
Serum creatinine, mg/dL 1.02±0.42 0.94±0.26 <0.0001
cKD 22.5 (1,173) 7.1 (3,431) <0.0001
anemia 12.1 (631) 3.7 (1,786) <0.0001
in those with cKD 28.0 (328) 11.6 (399) <0.0001
In those without CKD 7.5 (303) 3.1 (1,387) <0.0001
hemoglobin, g/dl 14.1±1.5 14.6±1.4 <0.0001
Serum iron, µ/dL 78.5±29.9 87.5±34.7 <0.0001
hDlc, mg/dl 45.6±12.2 50.1±14.6 <0.0001
lDlc, mg/dl 98.6±36.5 114.1±34.7 <0.0001
White blood cell count, ×103/µL 7.6±3.1 7.3±2.2 <0.0001
crP, mg/l 2.8 (1.2–6.3) 1.8 (0.80–4.20) <0.0001
PFaS
PFHxS, ng/mL 2.7 (1.7–4.3) 3.0 (1.9–4.8) <0.0001
PFOa, ng/ml 28.6 (12.6–72.7) 28.0 (13.6–71.4) 0.15
PFOS, ng/ml 21.2 (13.7–31.4) 20.2 (13.6–29.1) 0.11
PFna, ng/ml 1.4 (1.0–1.8) 1.4 (1.1–1.8) <0.0001
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HDLc, high-density lipoprotein 
cholesterol; LDLc, low-density lipoprotein cholesterol; PFAS, perfluoroalkyl acids; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic 
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that existed even among those with CKD. Consistent with 
this, they also tended to have a lower serum iron concentra-
tion than persons without diabetes. Lipid and inflammatory 
marker profiles also tended to be worse in persons with 
diabetes. Although there were no differences observed for 
mean levels of PFOA or PFOS by diabetes, differences were 
observed for PFHxS and PFNA.
The prevalence of CKD was 22% among those with 
diabetes and 7% among those without diabetes. In multivari-
able analyses controlling for age, sex, diabetes duration (in 
those with diabetes), BMI, lipids, white blood cell count, 
CRP, hemoglobin, and iron, PFAS were inversely associated 
with CKD in those with diabetes but positively associated 
with CKD in those without diabetes (P-interaction <0.0001 
for each PFAS and diabetes). This is depicted graphically 
for PFOA and PFOS in Figure 1, which shows that for 
every natural log increase in serum PFOA levels, those with 
diabetes had an 8% reduction in the likelihood of having 
CKD whereas those without diabetes had a nonsignificant 
1% reduced likelihood. For PFOS, there was a 20% reduced 
likelihood of CKD for those with diabetes with each natural 
log increase in serum PFOS levels, but an 8% increase in the 
odds of CKD for those without diabetes. Similar relationships 
were also observed for PFHxS and PFNA exposure.
Figure 2 shows the multivariable adjusted relationship of 
each of the PFAS with kidney function, stratified by anemia 
and CKD status among those with (Figure 2A) and without 
(Figure 2B) diabetes. In the absence of diabetes, for each 
of the PFAS, the strongest relationship was among those 
with both anemia and CKD, which demonstrated a positive 
relationship, ie, an increased eGFR. This was followed by a 
moderate, though still positive, relationship among those with 
CKD but no anemia. In the diabetic population with anemia 
but no CKD, a weak, though still positive, relationship was 
observed between the PFAS and eGFR. For those with neither 
anemia nor CKD, PFAS demonstrated an inverse relationship 
with eGFR. The P-value for linear trend for the beta coef-
ficients in the strength of the relationship of perfluoroalkyl 
substances with eGFR among the four anemia-CKD groups 
was <0.0001 for each PFAS.
Figure 2 also shows that the same general pattern in the 
relationship of PFAS with kidney function by anemia and 
CKD status that was observed for those with diabetes was 
apparent in those without diabetes as well. The strongest 
relationship was observed among those with both anemia 
and CKD, with the relationship progressively becoming 
attenuated before becoming inversely related among those 
with neither anemia nor CKD. However, except for those with 
Figure 1 Relationship of PFOA and PFOS with CKD, stratified by diabetes status. Gray lines = PFOA. Black lines = PFOS. Analyses adjusted for age, sex, BMI, HDLc, LDLc, 
white blood cell count, CRP, hemoglobin, and iron.
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; CRP, C-reactive protein; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein 
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PFAS and renal function in CKD and diabetes
neither anemia nor CKD, the relationships between PFAS and 
eGFR tended to be weaker among those without diabetes.
In the population as a whole, for each natural log increase 
in PFAS there was an approximately two- to fourfold greater 
odds of being in the normal eGFR range than in the stage 
4–5 CKD range. Odds ratios (95% CIs) for being in one of 
the three other eGFR categories >30 mL/min/1.73 m2, ie, 
CKD stages higher than 4, were 2.25 (1.89–2.67) to 2.50 
(2.14–2.92) for PFHxS, 1.61 (1.44–1.81) to 1.66 (1.48–1.86) 
for PFOA, 1.88 (1.68–2.11) to 2.38 (2.11–2.68) for PFOS, 
and 2.84 (2.29–3.54) to 3.68 (2.89–4.69), for PFNA, data 
not depicted. Thus, results were similar, but generally attenu-
ated for stages 2, 3a, and 3b, ie, a two- to fourfold greater 
likelihood of being in a higher eGFR range than in the <30 
range. This was true regardless of diabetes status, although 
the relationship was generally stronger among persons with 
Relationship of PFAS with eGFR among those with diabetes
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Figure 2 (A) Relationship of perfluoroalkyl substances with eGFR among the C8 Health Population, among persons with diabetes, stratified by anemia and CKD status. 
P-value <0.0001 for linear trend for the beta coefficients in the strength of the relationship of each of the perfluoroalkyl substances with eGFR among the four anemia-CKD 
groups. (B) Relationship of perfluoroalkyl substances with eGFR among the C8 Health Population, among persons without diabetes, stratified by anemia and CKD status. 
P-value<0.0001 for linear trend for the beta coefficients in the strength of the relationship of each of the perfluoroalkyl substances with eGFR among the four anemia-CKD 
groups. 
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PFAS, perfluoroalkyl acids; PFHxS, perfluorohexane sulfonate; PFNA, 
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diabetes (Table 2). There was a trend toward a stronger effect 
of PFAS in the highest eGFR group with diabetes and ane-
mia. The odds were generally lowest in those with anemia 
uncomplicated by diabetes, although they were still twice 
as likely to be in this category compared to the eGFR <30 
category with each natural log increase in PFAS (Table 3).
interpretation
The major finding of this study is that PFAS demonstrated 
a linear trend in the positive relationship with eGFR based 
on anemia-CKD status that represented a gradient of renal 
hypoxia. The strongest positive relationships were observed 
for those with both anemia and CKD, followed by those 
with CKD but no anemia. Little relationship was observed 
between PFAS and eGFR among those with anemia in the 
absence of CKD, while for those with neither anemia nor 
CKD an inverse relationship was observed between PFAS 
and eGFR. These associations were observed both among 
those with and without diabetes, although more pronounced 
among those with diabetes. We also found that persons with 
higher PFAS levels were two to four times more likely to be 
in the normal to mild kidney impairment range, or stages 3a 
or 3b CKD, than in stages 4–5 CKD. Our data suggest that 
the high oxygen carrying capacity of PFAS may be beneficial 
for renal function among persons with CKD, likely due to 
protection against hypoxia-induced progression toward renal 
failure. Our data also suggest that this protective relationship 
may be more pronounced in diabetes.
Perfluorocarbons are hydrogen carbon chains in where 
the hydrogen atoms have been replaced by fluorine. This 
fluorine substitution of hydrogen makes PFAS very efficient 
oxygen carriers. The oxygen solubility of perfluorocarbons 
has been reported to be 25 times greater than either blood 
or water.22,38 However, their oxygen binding constant is neg-
ligible, and thus they are more efficient than hemoglobin in 
delivering oxygen to surrounding tissues. As such, they have 
been used as blood substitutes,19,20 in the development of 
synthetic blood, and in the preservation of organs harvested 
for transplants.22 The high oxygen transport ability of per-
fluorocarbons has been shown to reduce the hypoxia-induced 
organ damage associated with kidney and pancreas organ 
preservation.22,23,25 We speculate that it is this high oxygen 
Table 2 Multivariable adjusteda association of PFAS with stage of kidney function, stratified by diabetes status, OR (95% CI)
Characteristics Diabetic population Non-diabetic population
PFHxS
<30, ml/min/1.73 m2 Ref Ref
30–44, ml/min/1.73 m2 2.05 (1.57–2.68) 2.30 (1.83–2.90)
45–59, ml/min/1.73 m2 2.68 (2.07–3.47) 2.37 (1.87–2.84)
60–89, ml/min/1.73 m2 2.77 (2.16–3.56) 2.29 (1.86–2.81)
≥90, ml/min/1.73 m2 2.49 (1.92–3.23) 2.07 (1.69–2.55)
PFOa
<30, ml/min/1.73 m2 Ref Ref
30–44, ml/min/1.73 m2 1.48 (1.23–1.80) 1.69 (1.44–2.00)
45–59, ml/min/1.73 m2 1.47 (1.23–1.76) 1.70 (1.46–1.98)
60–89, ml/min/1.73 m2 1.56 (1.31–1.89) 1.71 (1.47–1.99)
≥90, ml/min/1.73 m2 1.57 (1.31–1.90) 1.66 (1.42–1.93)
PFOS
<30, ml/min/1.73 m2 Ref Ref
30–44, ml/min/1.73 m2 1.90 (1.54–2.35) 2.47 (2.04–3.00)
45–59, ml/min/1.73 m2 2.34 (1.92–2.87) 2.36 (2.02–2.75)
60–89, ml/min/1.73 m2 2.51 (2.07–3.03) 2.12 (1.83–2.44)
≥90, ml/min/1.73 m2 2.32 (1.90–2.84) 1.78 (1.54–2.06)
PFna
<30, ml/min/1.73 m2 Ref Ref
30–44, ml/min/1.73 m2 3.08 (2.10–4.54) 4.04 (2.94–5.54)
45–59, ml/min/1.73 m2 3.27 (2.28–4.68) 3.58 (2.71–4.73)
60–89, ml/min/1.73 m2 3.74 (2.63–5.31) 3.16 (2.41–4.15)
≥90, ml/min/1.73 m2 3.90 (2.70–5.65) 2.64 (2.10–3.48)
Notes: aAnalyses adjusted for age, sex, BMI, HDLc, LDLc, white blood cell count, CRP, hemoglobin, and iron.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; PFAS, perfluoroalkyl 
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PFAS and renal function in CKD and diabetes
carrying capacity that accounted for the positive relation-
ship between PFAS and eGFR among those with CKD in 
our population, as CKD is a state where hypoxia greatly 
accelerates the progression to renal failure. The stronger 
relationship of the sulfonate PFAS (PFHxS and PFOS), 
whose half-lives are generally much longer than PFOA,17,18 
supports this. By circulating longer in the system, their 
potential protection from hypoxia-induced glomerular dam-
age would be prolonged and thus the relationship of eGFR 
with those particular PFAS would be stronger.
The chronic hypoxia theory postulates that after an initial 
insult or injury to the kidney, there is some scarring that 
leads to hypoxia because of the greater diffusion distance to 
capillaries.4,30,39,40 This capillary hypoxia results in fibroblast 
deposition, the laying down of extracellular matrix and neu-
trophils. This leads to more sclerosis and hypoxia, a cycle 
which eventually results in organ failure. Diabetes, whether 
it be through increased formation of advanced glycation end 
products and the structural changes they cause on kidney 
tubules, or via the increased oxygen renal consumption 
resulting from hyperglycemia, may be an insult to the kid-
ney resulting in increased hypoxia. Hyperglycemia results 
in greater renal oxygen consumption to transport sodium.31 
This leads to greater renal blood flow and its sequelae of 
hyperfiltration. This hyperfiltration may eventually result in 
hypoxia due to the increased oxygen consumption.
Earlier data in experimental studies suggested that 
perfluorocarbon emulsion was associated with greater 
renal function impairment;28 however, more recent data in 
experimental models found that retrograde renal perfusion 
with perfluorocarbon emulsion increased systemic venous 
oxygenation and renal preservation.27 There was higher 
systemic venous oxygenation, a lower decrease in creatinine 
clearance, and less histological evidence of ischemic dam-
age.27 The results of the natural experiment we report on 
suggest that the high oxygen carrying capacity of the PFAS 
that were circulating in the blood and bathing the tissues of 
the C8 Health Population were protective against hypoxia-
induced decline in kidney function in those with CKD. This 
relationship appeared to be stronger in those with diabetes, for 
Table 3 Multivariable adjusteda association of PFAS with stage of kidney function, stratified by diabetes and anemia status, OR (95% CI)
Characteristics Diabetic population Non-diabetic population
Anemia No anemia Anemia No anemia
PFHxS
<30, ml/min/1.73 m2 Ref Ref Ref Ref
30–44, ml/min/1.73 m2 1.99 (1.38–2.86) 2.15 (1.42–3.27) 1.69 (1.17–2.44) 2.71 (2.02–3.65)
45–59, ml/min/1.73 m2 3.18 (2.17–4.67) 2.66 (1.79–3.95) 1.73 (1.23–2.44) 2.66 (2.02–3.49)
60–89, ml/min/1.73 m2 2.64 (1.83–3.80) 2.89 (1.97–4.24) 1.72 (1.25–2.36) 2.63 (2.01–3.45)
≥90, ml/min/1.73 m2 3.20 (2.00–5.13) 2.55 (1.73–3.77) 1.80 (1.29–2.52) 2.37 (1.81–3.11)
PFOa
<30, ml/min/1.73 m2 Ref Ref Ref Ref
30–44, ml/min/1.73 m2 1.28 (0.99–1.65) 1.83 (1.34–2.50) 1.60 (1.24–2.06) 1.72 (1.37–2.15)
45–59, ml/min/1.73 m2 1.33 (1.04–1.70) 1.75 (1.30–2.35) 1.74 (1.37–2.21) 1.69 (1.37–2.10)
60–89, ml/min/1.73 m2 1.41 (1.11–1.80) 1.84 (1.37–2.47) 1.53 (1.22–1.91) 1.72 (1.39–2.12)
≥90, ml/min/1.73 m2 1.79 (1.33–2.42) 1.82 (1.36–2.46) 1.59 (1.26–2.02) 1.67 (1.35–2.06)
PFOS
<30, ml/min/1.73 m2 Ref Ref Ref Ref
30–44, ml/min/1.73 m2 2.20 (1.58–3.07) 1.74 (1.31–2.34) 1.98 (1.42–2.74) 2.77 (2.17–3.53)
45–59, ml/min/1.73 m2 2.47 (1.78–3.43) 2.33 (1.77–3.06) 2.08 (1.54–2.80) 2.49 (2.05–3.02)
60–89, ml/min/1.73 m2 2.27 (1.68–3.07) 2.58 (1.99–3.34) 1.82 (1.42–2.33) 2.24 (1.86–2.69)
≥90, ml/min/1.73 m2 2.83 (1.88–4.26) 2.33 (1.78–3.05) 2.09 (1.58–2.77) 1.86 (1.54–2.24)
PFna
<30, ml/min/1.73 m2 Ref Ref Ref Ref
30–44, ml/min/1.73 m2 3.16 (1.86–5.37) 3.17 (1.74–5.80) 3.23 (1.92–5.44) 4.31 (2.87–6.49)
45–59, ml/min/1.73 m2 3.30 (1.98–5.47) 3.49 (2.00–6.11) 2.73 (1.70–4.38) 3.82 (2.66–5.50)
60–89, ml/min/1.73 m2 3.33 (2.03–5.47) 4.13 (2.40–7.13) 2.49 (1.61–3.85) 3.36 (2.35–4.81)
≥90, ml/min/1.73 m2 4.38 (2.28–8.42) 4.25 (2.44–7.43) 2.59 (1.62–4.16) 2.79 (1.95–4.00)
Notes: aAnalyses adjusted for age, sex, BMI, HDLc, LDLc, white blood cell count, CRP, hemoglobin, and iron.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; PFAS, perfluoroalkyl 
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whom chronic hyperglycemia-induced oxygen consumption 
would likely normally result in increased hypoxia.
In general population data from the National Health and 
Examination Survey for the years 1999–2008, the perfluoro-
alkyl substances PFOA and PFOS were positively associated 
with the presence of CKD and inversely associated with 
eGFR.41 As in our population, in the NHANES population 
their relationship with eGFR was stronger in persons without 
CKD. Although the authors performed subgroup analyses by 
age, sex, race, educational level, and BMI, diabetes was only 
used as a co-variable and controlled for in the analyses. Simi-
larly, in a study conducted by the C8 Health Study science 
panel investigating the relationship of PFOA with chronic 
diseases in the current study population, analyses examining 
the relationship between PFOA and kidney disease in the 
population as a whole as well as specifically in those without 
diabetes were conducted. However, the relationship of PFOA 
in those with diabetes was not examined, nor whether there 
was an interaction by diabetes status.
Consistent with what is known about anemia in diabe-
tes,42–44 we observed high frequencies of anemia among the 
diabetic population with CKD relative to the non-diabetic 
population with CKD. There was also a much greater preva-
lence of anemia among persons with diabetes in the non-CKD 
population. Anemia is a condition in which red blood cell 
mass decreases below the level needed to meet physiological 
needs. As a primary function of red blood cells is to deliver 
oxygen from the lungs to tissues, anemia is thus essentially a 
decreased ability of the blood to oxygenate tissues, resulting 
in tissue hypoxia. Reduced red cell mass leads to reduced 
renal tissue oxygenation. In the context of CKD, where renal 
damage has already been established, this hypoxia leads 
to further nephron destruction and renal interstitial injury 
and fibrosis. Since the peritubular interstitial cells are the 
primary producers of erythropoietin, which in turn gener-
ates hemoglobin, the consequent reduction in functional 
renal mass due to the hypoxia-induced nephron destruction 
and renal interstitial fibrosis results in a feed forward cycle 
toward renal failure.
We found a strong positive relationship between PFAS 
and eGFR in our CKD population with anemia. This was true 
regardless of the presence of diabetes, although the relation-
ship appeared to be stronger among those with diabetes. To 
a lesser extent, though still strong, this apparently protec-
tive relationship was also observed in the CKD population 
without anemia. Very weak relationships were observed 
between PFAS and eGFR in the anemic population in the 
absence of CKD. Thus, the apparent salutary relationship 
of PFAS among persons with kidney disease appears to be 
its enhanced tissue oxygenation, and thus protection from 
hypoxia. This relationship is particularly strong in the sub-
population with very low hemoglobin levels, ie, the popula-
tion with anemia. The profound relationship we saw between 
PFAS and eGFR among persons with CKD complicated by 
anemia is analogous to the effect of perfluorocarbon use in 
acute normovolemic hemodilution during surgery, where 
perfluorocarbon-carried oxygen is preferentially, as compared 
to hemoglobin, delivered to tissues.19
Despite its ubiquitous presence and its relationship with 
accelerated progression to renal failure and reduced qual-
ity of life, treatment of anemia in CKD is controversial. 
Treatment of anemia with erythropoietin-stimulating agents 
(ESAs), although associated with an increased quality of life, 
has not been shown to prolong survival.45,46 To the contrary, 
ESAs have been associated with increased cardiovascular 
complications of kidney disease and mortality.45,47 Our data 
suggest that among persons with CKD, development of per-
fluorocarbon therapeutics for the treatment of renal hypoxia 
may be a safer alternative.
Our study has several limitations. First, due to the 
cross-sectional nature of our data, we cannot say that PFAS 
are protective against progression of CKD. Our measure-
ment was a single snapshot in time. PFAS are known to be 
preferentially excreted by the action of organic anion trans-
porter proteins (OATs). PFAS are filtered at the glomerulus, 
secreted into the urine by OAT1 transporters on the tubule, 
and reabsorbed from the urine by OAT4 transporters in the 
tubule. Thus, if there are changes to some but not all of these 
components, the serum levels could change but it may not 
reflect the levels when the injury was occurring. However, if 
the chronic hypoxia hypothesis of the progression of CKD 
is true, then given the high oxygen carrying and diffusion 
capacity of PFAS, this entire transport process of PFAS from 
the glomerulus, the excretion of PFAS into the urine by OAT1 
transporters on the tubule, and then the reabsorption from 
the urine to the tubules by OAT4 transporters would support 
a protective role of PFAS in the progression of CKD.
It could also be argued that the inverse relationship 
between PFAS and CKD in our population was due to reverse 
causality since those with CKD would have a decreased abil-
ity to filter PFAS, resulting in higher PFAS levels. However, 
if reverse causality was the explanation of our findings, we 
should have also observed an inverse relationship between 
eGFR and PFAS, ie, increasing PFAS with decreasing eGFR, 
in those with CKD. In fact, the opposite was observed. 
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PFAS and renal function in CKD and diabetes
PFAS and eGFR in those without CKD. We posit that this 
inverse relationship in those without CKD was due to reverse 
causality, as also suggested in the study by Dhingra et al,48 
since the initial insult resulting in the progressive hypoxic-
scarring cycle had not occurred yet in those without CKD, 
and thus this salutary effect of the high oxygen carrying and 
diffusion capacity of the perfluorocarbons on renal tubules 
would not be operant in those with normal or mildly impaired 
renal function. The fact that there was an apparent threshold 
effect, ie, PFAS were fairly similarly associated with being 
in any one of the higher kidney function strata than in the 
eGFR <30 strata, supports the hypothesis of hypoxia-induced 
progression from CKD to renal failure. Our data suggest that 
PFAS may protect against this. Further evaluation in animal 
models would be useful.
In conclusion, although the cross-sectional nature of our 
study limits causal inferencing, the strong, positive associa-
tions observed between PFAS and kidney function in those 
with CKD, and to a lesser extent anemia, suggest that PFAS 
may protect against further decline in renal function in these 
populations. Owing to the increased hypoxia in diabetes, 
these substances may have an even stronger salutary effect 
on renal function in persons with diabetes complicated by 
kidney disease. Given the strong evidence linking hypoxia 
to progression of CKD, the high oxygen carrying capacity 
of PFAS, and the suggestive findings of our study, prospec-
tive studies examining the relationship of PFAS with renal 
function decline in persons with CKD, anemia, and diabetes 
are warranted.
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